Best Ideas Portfolio

Official PayPal Seal

This Firm Just Registered a 10 on the Valuentum Buying Index

publication date: Aug 31, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
This firm's new treatment has a high rate of effectiveness, and its lack of competition has fueled rapid adoption in the medical community. This firm has so much monopolistic power that Congress is complaining that it is putting too much budgetary pressure on Medicare and Medicaid. The company just registered the highest rating of a 10 on the Valuentum Buying Index (equivalent to a "we'd consider buying" rating), and we think there is considerable share-price upside. The stock not only trades at a material discount to its discounted cash-flow-derived intrinsic value, but its earnings multiple is but a fraction of its peer group's.

Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.